Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

A Closer Look At The US Pricing Pushback

This article was originally published in Scrip

Executive Summary

Critics of high prescription drug prices are making headlines in the US, and politicians on the presidential campaign trail and on Capitol Hill are talking about government-imposed price controls. But the real news may be unfolding behind the scenes in the private health insurance market, as Cathy Kelly finds out.

You may also be interested in...



Cigna’s Bradbury Talks PCSK9 Contracts And Value Versus Volume

Amgen and Sanofi/Regeneron will pay deeper discounts if patients taking Repatha and Praluent don’t experience similar levels of LDL-cholesterol lowering as was seen in clinical trials.

Medicare Part D Redesign Could Expand Rebate-Driven Formulary Exclusions In Program

Increased application of utilization management controls expected as plans face higher costs under the redesign. However, the formulary advantages available to drugs in the protected classes may lead developers to sharpen their focus on those categories.

Leqembi Label Recommends Alzheimer’s Patient Registry: A Nod To Medicare Evidence Demands?

FDA-approved language recommending ongoing patient monitoring through a registry is unusual but not unprecedented to address potential safety concerns.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

SC063924

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel